Contrast Induced Nephropathy News and Research

RSS

Contrast-induced nephropathy (CIN) is a common complication of radiographic procedures and is the third leading cause of hospital aquired renal failure. It is associated with significant morbidity and mortality.

PLC's RenalGuard REMEDIAL II trial against CIN presented at ACC.11

PLC Systems Inc., a company focused on innovative medical device technologies, announced that final results from the REMEDIAL II investigator-sponsored clinical trial of RenalGuard in Italy were presented today.

5 Apr 2011

PLC's RenalGuard System REMEDIAL II trial final results to be presented at ACC conference

PLC Systems Inc., a company focused on innovative medical device technologies, today reported that final results from the REMEDIAL II investigator-sponsored clinical trial of its RenalGuard System™ in Italy are scheduled to be presented at 11:57 a.m. CT on Monday, April 4, 2011, at the American College of Cardiology's 60th Annual Scientific Session & Expo in New Orleans, Louisiana. Additionally, PLC will be demonstrating RenalGuard at its booth at the conference.

2 Apr 2011

PLC Systems third quarter net loss decrease to $5,000

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today reported financial results for the three- and nine-month periods ended September 30, 2010.

15 Nov 2010

CorMedix awarded $488,959 QTDP program grant to develop Neutrolin and Deferiprone clinical programs

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it has been awarded two grants totaling $488,959 under the qualifying therapeutic discovery project ("QTDP") program established under Section 48D of the Internal Revenue Code. These grants were awarded based on applications CorMedix submitted for both its Neutrolin® and Deferiprone programs.

4 Nov 2010

PLC Systems second-quarter total revenues decrease to $1,019,000

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today reported financial results for the three- and six month periods ended June 30, 2010.

16 Aug 2010

CorMedix joins broad-market Russell Microcap Index

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that CorMedix has been added to the broad-market Russell Microcap® Index when Russell Investments reconstituted its comprehensive set of U.S. and global equity indexes on June 25, 2010.

29 Jun 2010

CorMedix announces dosing of first patient with CRMD-001 in Phase II clinical trial

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced dosing of the first patient with CRMD-001 (a proprietary formulation of deferiprone) in a randomized, double-blind, placebo-controlled clinical trial.

25 Jun 2010

PLC Systems reports total revenues of $1,062,000 for first-quarter 2010

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today reported financial results for the three-month period ended March 31, 2010.

14 May 2010

U.S. Patent Office issues Notices of Allowance covering PLC Systems's RenalGuard technology

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today reported that the U.S. Patent and Trademark Office had issued Notices of Allowance for two of PLC's patent applications associated with its RenalGuard® technology.

16 Apr 2010

ACIST Medical Systems to provide CVi contrast injection system to HealthTrust Purchasing Group

ACIST Medical Systems, Inc., a world-leading provider of contrast-delivery systems for cardiology and radiology imaging, announced today that HealthTrust Purchasing Group, LP (HealthTrust), Brentwood, Tenn., one of the leading health care group purchasing organizations, has awarded the company a three-year contract, effective December 1, 2009, for ACIST cardiovascular injection technology, the ACIST | CVi® Contrast Delivery System.

9 Mar 2010

Updated results from MYTHOS clinical trial of RenalGuard presented at AHA meeting

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that updated results from the MYTHOS investigator-sponsored clinical trial of RenalGuard(®) were presented at the American Heart Association (AHA) Scientific Sessions 2009, on Sunday, November 15 in Orlando, Florida.

2 Dec 2009

Financial results for third-quarter 2009 announced by PLC Systems

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today reported financial results for the three and nine month periods ended September 30, 2009.

11 Nov 2009

PLC Systems' RenalGuard to be utilized in a live case transmission at the GISE 2009 conference

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that its RenalGuard System(TM) will be utilized as part of a live case transmission from the Clinica Mediterranea, Naples, Italy, to the 30th Congresso Nazionale della Societa' Italiana di Cardiologia Invasiva (GISE) during the conference.

19 Oct 2009

The Transcatheter Cardiovascular Therapeutics 2009 to feature PLCs' RenalGuard System

PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate its RenalGuard System(TM) at Transcatheter Cardiovascular Therapeutics (TCT) 2009, sponsored by the Cardiovascular Research Foundation, September 21 - 25, 2009, in San Francisco, California. More than 11,000 clinicians and professionals are expected to attend this event.

21 Sep 2009

Initial abstract for the clinical study of PLC's RenalGuard System published

PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that the initial abstract for the investigator-sponsored clinical study of its RenalGuard System(TM) has been published, in advance of the annual meeting of the European Society of Cardiology, August 29 - September 2, 2009 in Barcelona, Spain, on the ESC website.

26 Aug 2009

Sodium bicarbonate based hydration is optimal treatment strategy to prevent contrast-induced nephropathy

The research, published in the open access journal BMC Medicine, shows that although the benefit may have been overestimated by previous studies, sodium bicarbonate is clearly superior to normal saline.

12 May 2009

CT scan can harm kidneys, but cheap drug can help

As more and more Americans undergo CT scans and other medical imaging scans involving intense X-rays, a new study suggests that many of them should take a pre-scan drug that could protect their kidneys from damage.

20 Feb 2008

Sodium Bicarbonate vs. Sodium Chloride in persons undergoing coronary angiography

In patients undergoing cardiac catheterization, contrast dye injection can sometimes cause contrast-induced nephropathy (CIN), otherwise known as acute renal failure.

3 Apr 2007

Performing x-rays using iodine dye increases risk for kidney failure

Performing x-rays using iodine dye places patients with impaired kidney function at increased risk for kidney failure. Known as Contrast-Induced Nephropathy (ne-FROPP-a- thee) or ''CIN,'' this complication is the third most common cause of hospital-acquired kidney failure in the United States and Europe, accounting for 10-12 percent of all such cases.

1 Apr 2007